Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia

Marilyn S. Bartlett, William C. Angus, Margaret M. Shaw, Pamela J. Durant, Chao-Hung Lee, Juan M. Pascale, James W. Smith

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Well-proven mouse and rat models were used to show that polyclonal antisera to Pneumocystis carinii protect against P. carinii pneumonia. Antibodies were obtained from animals that were allowed to recover from severe P. carinii pneumonia after immunosuppression had been stopped and which then were given a booster injection of P. carinii from the same animal species. Mice immunosuppressed with corticosteroids or antibodies to L3T4+ lymphocytes (which are comparable to CD4 cells of humans) and transtracheally inoculated with mouse P. carinii did not develop P. carinii pneumonia if they were passively immunized with antiserum, while mice immunosuppressed and inoculated by identical procedures but not given antibodies developed severe infections. Rats immunosuppressed with corticosteroids and inoculated with rat P. carinii had less severe infections if they were given rat anti-P. carinii antisera. The polyclonal antisera developed in mice provided greater protection for the mice than the polyclonal rat antisera did for the rats; however, the potencies and compositions of the antisera were not quantitated and probably differed. Since both rats and mice can be protected from P. carinii infections with polyclonal antisera, it may be possible to develop vaccines that will elicit protective antibodies in humans.

Original languageEnglish
Pages (from-to)74-77
Number of pages4
JournalClinical and Diagnostic Laboratory Immunology
Volume5
Issue number1
StatePublished - 1998

Fingerprint

Pneumocystis carinii
Rats
Immune Sera
Pneumonia
Antibodies
Pneumocystis Pneumonia
Adrenal Cortex Hormones
Animals
Pneumocystis Infections
Lymphocytes
Infection
Immunosuppression
Vaccines
Cells
Injections
Chemical analysis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Bartlett, M. S., Angus, W. C., Shaw, M. M., Durant, P. J., Lee, C-H., Pascale, J. M., & Smith, J. W. (1998). Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clinical and Diagnostic Laboratory Immunology, 5(1), 74-77.

Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. / Bartlett, Marilyn S.; Angus, William C.; Shaw, Margaret M.; Durant, Pamela J.; Lee, Chao-Hung; Pascale, Juan M.; Smith, James W.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 5, No. 1, 1998, p. 74-77.

Research output: Contribution to journalArticle

Bartlett, MS, Angus, WC, Shaw, MM, Durant, PJ, Lee, C-H, Pascale, JM & Smith, JW 1998, 'Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia', Clinical and Diagnostic Laboratory Immunology, vol. 5, no. 1, pp. 74-77.
Bartlett MS, Angus WC, Shaw MM, Durant PJ, Lee C-H, Pascale JM et al. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clinical and Diagnostic Laboratory Immunology. 1998;5(1):74-77.
Bartlett, Marilyn S. ; Angus, William C. ; Shaw, Margaret M. ; Durant, Pamela J. ; Lee, Chao-Hung ; Pascale, Juan M. ; Smith, James W. / Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. In: Clinical and Diagnostic Laboratory Immunology. 1998 ; Vol. 5, No. 1. pp. 74-77.
@article{b1ebfd1b71a64dd7b2c479807bdcbdb6,
title = "Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia",
abstract = "Well-proven mouse and rat models were used to show that polyclonal antisera to Pneumocystis carinii protect against P. carinii pneumonia. Antibodies were obtained from animals that were allowed to recover from severe P. carinii pneumonia after immunosuppression had been stopped and which then were given a booster injection of P. carinii from the same animal species. Mice immunosuppressed with corticosteroids or antibodies to L3T4+ lymphocytes (which are comparable to CD4 cells of humans) and transtracheally inoculated with mouse P. carinii did not develop P. carinii pneumonia if they were passively immunized with antiserum, while mice immunosuppressed and inoculated by identical procedures but not given antibodies developed severe infections. Rats immunosuppressed with corticosteroids and inoculated with rat P. carinii had less severe infections if they were given rat anti-P. carinii antisera. The polyclonal antisera developed in mice provided greater protection for the mice than the polyclonal rat antisera did for the rats; however, the potencies and compositions of the antisera were not quantitated and probably differed. Since both rats and mice can be protected from P. carinii infections with polyclonal antisera, it may be possible to develop vaccines that will elicit protective antibodies in humans.",
author = "Bartlett, {Marilyn S.} and Angus, {William C.} and Shaw, {Margaret M.} and Durant, {Pamela J.} and Chao-Hung Lee and Pascale, {Juan M.} and Smith, {James W.}",
year = "1998",
language = "English",
volume = "5",
pages = "74--77",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia

AU - Bartlett, Marilyn S.

AU - Angus, William C.

AU - Shaw, Margaret M.

AU - Durant, Pamela J.

AU - Lee, Chao-Hung

AU - Pascale, Juan M.

AU - Smith, James W.

PY - 1998

Y1 - 1998

N2 - Well-proven mouse and rat models were used to show that polyclonal antisera to Pneumocystis carinii protect against P. carinii pneumonia. Antibodies were obtained from animals that were allowed to recover from severe P. carinii pneumonia after immunosuppression had been stopped and which then were given a booster injection of P. carinii from the same animal species. Mice immunosuppressed with corticosteroids or antibodies to L3T4+ lymphocytes (which are comparable to CD4 cells of humans) and transtracheally inoculated with mouse P. carinii did not develop P. carinii pneumonia if they were passively immunized with antiserum, while mice immunosuppressed and inoculated by identical procedures but not given antibodies developed severe infections. Rats immunosuppressed with corticosteroids and inoculated with rat P. carinii had less severe infections if they were given rat anti-P. carinii antisera. The polyclonal antisera developed in mice provided greater protection for the mice than the polyclonal rat antisera did for the rats; however, the potencies and compositions of the antisera were not quantitated and probably differed. Since both rats and mice can be protected from P. carinii infections with polyclonal antisera, it may be possible to develop vaccines that will elicit protective antibodies in humans.

AB - Well-proven mouse and rat models were used to show that polyclonal antisera to Pneumocystis carinii protect against P. carinii pneumonia. Antibodies were obtained from animals that were allowed to recover from severe P. carinii pneumonia after immunosuppression had been stopped and which then were given a booster injection of P. carinii from the same animal species. Mice immunosuppressed with corticosteroids or antibodies to L3T4+ lymphocytes (which are comparable to CD4 cells of humans) and transtracheally inoculated with mouse P. carinii did not develop P. carinii pneumonia if they were passively immunized with antiserum, while mice immunosuppressed and inoculated by identical procedures but not given antibodies developed severe infections. Rats immunosuppressed with corticosteroids and inoculated with rat P. carinii had less severe infections if they were given rat anti-P. carinii antisera. The polyclonal antisera developed in mice provided greater protection for the mice than the polyclonal rat antisera did for the rats; however, the potencies and compositions of the antisera were not quantitated and probably differed. Since both rats and mice can be protected from P. carinii infections with polyclonal antisera, it may be possible to develop vaccines that will elicit protective antibodies in humans.

UR - http://www.scopus.com/inward/record.url?scp=0031929631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031929631&partnerID=8YFLogxK

M3 - Article

C2 - 9455884

AN - SCOPUS:0031929631

VL - 5

SP - 74

EP - 77

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 1

ER -